Compare GPGI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPGI | IBRX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.4B |
| IPO Year | N/A | 2015 |
| Metric | GPGI | IBRX |
|---|---|---|
| Price | $17.10 | $7.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $12.57 |
| AVG Volume (30 Days) | 4.7M | ★ 24.1M |
| Earning Date | 03-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.06% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $770.85 | $88.59 |
| Revenue Next Year | $125.54 | $131.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $15.84 | $1.83 |
| 52 Week High | $25.66 | $12.43 |
| Indicator | GPGI | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.48 | 48.47 |
| Support Level | $16.41 | $2.25 |
| Resistance Level | $18.51 | $8.28 |
| Average True Range (ATR) | 0.94 | 0.93 |
| MACD | 0.04 | -0.24 |
| Stochastic Oscillator | 40.88 | 39.00 |
GPGI Inc is a diversified holding platform comprising businesses operating in multiple industries. The platform focuses on acquiring, owning, and scaling operating companies. It currently includes CompoSecure and Husky Technologies. CompoSecure provides technology and manufacturing solutions related to metal payment cards, security, and authentication. Its products and services are used by financial institutions, fintech companies, and other customers. Husky designs and manufactures industrial equipment and provides aftermarket services. Its equipment is used in the production of plastic products, including beverage and food containers, medical devices, and consumer electronics components.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.